Saturday 17 October 2026 Export OKYO’s income statement to Excel — free account

OKYO Pharma Limited Sponsored ADR

OKYO Healthcare Biotechnology

Insiders bought in the last twelve months.

1.41 0.02 −1.40%

Follow OKYO

Alert me

Market cap: $75.1M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.14

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	7	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 95.29%

Capital & Financial Ratios $m

Market Cap 75.05

Revenue —

Net Income (23.60)

Free Cash Flow (9.53)

Net Debt (20.59)

Current Ratio 2.43

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 86.44

Past 5Y EPS Growth —

This Y EPS Growth 20.59%

Next Y EPS Growth (200.00%)

Next Y revenue growth —

Next 5Y EPS Growth 11.21%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	4	1	2	21
Receivables	1	1	2	0
Inventory	—	—	—	—
Other	—	—	—	—
	5	2	4	21

	2023	2024	2025	2026
Payables	4	7	8	9
ST’ Debt	2	—	—	—
Other	—	—	—	—
	7	7	9	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	18.32%	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	(6)
’25	—	—	—	—	(2)
’24	—	—	—	—	(9)
’23	—	—	—	—	(8)
’22	—	—	—	—	(5)
’21	—	—	(1)	—	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	(6)	—	(2)	—	(6)
’25	(2)	—	0	—	(2)
’24	(9)	—	—	—	(9)
’23	(8)	—	(3)	—	(8)
’22	(5)	—	(3)	—	(5)
’21	(2)	—	(1)	—	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	(0.24)
’25	—	—	—	—	(0.12)
’24	—	—	—	—	(0.57)
’23	—	—	—	—	(0.61)
’22	—	—	—	—	(0.36)
’21	—	—	0.00	—	(0.65)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	—	—	—	—	1.61	0.92	0.81	0.90	1.27	Analyst estimates 2027–2029 Powerpack
	High	—	—	—	—	—	6.11	7.00	1.95	3.35	3.20
People
People	Employees	—	—	—	—	2	3	3	3	4	5
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	(5)	(2)	(3)	(6)	(13)	(17)	(8)	(9)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	—	(5)	(2)	(3)	(6)	(13)	(17)	(8)	(9)
	Depreciation	—	—	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(0.01)	0.00	(0.65)	(0.36)	(0.61)	(0.57)	(0.12)	(0.24)
	Cash flow	—	—	0.00	0.00	(0.31)	(0.36)	(0.35)	(0.32)	(0.05)	(0.16)
	Capex	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	—	0.00	0.00	(0.31)	(0.36)	(0.35)	(0.32)	(0.05)	(0.16)
	Book value	—	—	0.00	0.00	1.03	0.20	(0.09)	(0.20)	(0.14)	0.33
	Shares, m	—	—	589	683	5	15	22	29	39	37
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(2)	(1)	(2)	(5)	(8)	(9)	(2)	(6)
	Capex	—	—	0	—	0	0	0	—	0	0
	Free cash flow	—	—	(2)	(1)	(2)	(5)	(8)	(9)	(2)	(6)
Balance, $m
Balance, $m	Working capital	—	—	0	0	5	3	(2)	(6)	(6)	12
	Total debt	—	—	—	0	0	—	2	—	—	—
	Net debt	—	—	(1)	0	(7)	(3)	(2)	(1)	(2)	(21)
	Shareholders’ equity	—	—	0	0	5	3	(2)	(6)	(6)	12
Returns, %
Returns, %	ROA	—	—	0.00	(227.14)	(87.22)	(95.35)	(279.27)	(498.89)	(180.37)	(72.60)
	ROIC	—	—	0.00	0.00	0.00	(1,575.19)	0.00	0.00	0.00	0.00
	ROE	—	—	0.00	(1,600.62)	(129.50)	(131.39)	(2,968.40)	424.20	82.36	(263.79)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PMN Promis Neurosciences	$78.0M	— (loss-making)	—	0.00%	n/m	−169.46% (below 0%: shrinking)	0.00%	0.00%	Compare
PTHS Pelthos Therapeutics Inc.	$77.6M	— (loss-making)	— (loss-making)	—	n/m	−1,614.99% (below 0%: shrinking)	76.86%	(111.02%)	Compare
TELO Telomir Pharmaceuticals, Inc.	$77.3M	— (loss-making)	—	—	n/m	−45.34% (below 0%: shrinking)	—	0.00%	Compare
NTRB Nutriband Inc.	$76.2M	— (loss-making)	4.6×	−29.72% (below 0%: shrinking)	n/m	+55.46% (above 0%: growing)	41.58%	(203.57%)	Compare
CRDF Cardiff Oncology, Inc.	$75.5M	— (loss-making)	— (loss-making)	−14.05% (below 0%: shrinking)	n/m	−41.36% (below 0%: shrinking)	100.00%	(9,245.19%)	Compare
ACRV Acrivon Therapeutics, Inc.	$75.4M	— (loss-making)	—	—	n/m	+12.59% (above 0%: growing)	0.00%	0.00%	Compare
OKYO OKYO Pharma Limited Sponsored ADR	$75.1M	— (loss-making)	—	—	n/m	+37.39% (above 0%: growing)	0.00%	—
PDSB PDS Biotechnology Corporation	$72.8M	— (loss-making)	—	—	n/m	+69.32% (above 0%: growing)	0.00%	0.00%	Compare
HRTX Heron Therapeutics, Inc.	$71.5M	— (loss-making)	— (loss-making)	+1.25% (above 0%: growing)	n/m	+78.75% (above 0%: growing)	69.28%	(5.43%)	Compare
Median of peers	$75.9M	—	—	−7.02%	—	−14.38%	41.58%	(2.71%)

All 614 Biotechnology stocks →

OKYO Pharma Limited Sponsored ADR (OKYO) key facts

OKYO Pharma Limited Sponsored ADR (OKYO) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, OKYO traded at $1.41, a market capitalization of $75.1 million.
Return on equity was −263.8% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.